cmAngio® vs KardiaAI
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your primary objective is to enhance cardiovascular risk assessment for women by automatically detecting and visualizing Breast Arterial Calcifications (BAC) on routine mammograms. This tool is ideal for radiology departments and women's health centers looking to integrate early cardiovascular insights without requiring additional patient procedures or radiation exposure.
View cmAngio® →Choose KardiaAI if…
Choose KardiaAI if you require an AI-powered software library for the analysis of ambulatory ECG rhythms, capable of detecting a wide range of cardiac conditions such as AFib, bradycardia, and tachycardia. This solution is best suited for integration into mobile applications or other ECG devices, providing medical-grade heart rhythm analysis for remote monitoring or point-of-care diagnostics.
View KardiaAI →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | KardiaAI |
|---|---|---|
| Pricing | Paid, out-of-pocket | Subscription-based for advanced features and services. |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Mobile app, cloud-based. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®cmAngiou00ae emphasizes quick installation and compatibility with any DICOM-compliant viewer, suggesting seamless integration into a radiologist's existing workflow. KardiaAI is an API library, meaning its direct usability for clinicians or patients depends on the front-end application built upon it, which requires developer effort for integration.
Clinical Value
KardiaAIKardiaAI offers direct detection of a range of critical cardiac arrhythmias, including AFib, bradycardia, and tachycardia, which are immediately actionable for diagnosis and patient management. While cmAngio provides valuable insights into cardiovascular risk through BAC detection, KardiaAI's direct diagnostic capabilities for acute and chronic heart conditions offer a broader and more immediate clinical impact.
Pricing & Value
KardiaAIKardiaAI offers transparent, publicly available subscription pricing with different tiers, allowing potential users to easily understand costs and assess value. cmAngio's pricing is not publicly available, requiring direct contact with the vendor, which hinders easy comparison and value assessment.
Enterprise Readiness
KardiaAIKardiaAI is designed as an API library for integration into various mobile apps, web platforms, and other ECG devices and software, demonstrating high flexibility for diverse enterprise deployments. While cmAngio integrates into existing DICOM viewers, KardiaAI's API-first approach allows for broader and more adaptable enterprise-level integrations across different digital health ecosystems.
Innovation
cmAngio®cmAngiou00ae demonstrates innovation by repurposing existing mammography data, primarily used for breast cancer screening, to detect Breast Arterial Calcifications (BAC) for cardiovascular risk assessment. This novel application leverages an established imaging modality for a secondary, yet critical, health insight. While KardiaAI offers advanced AI for ECG analysis, cmAngio's approach to extracting new value from existing clinical data presents a more unique and innovative application of AI in healthcare.
Support & Docs
KardiaAIAliveCor, the company behind KardiaAI, has a well-established ecosystem of consumer-facing devices and services with extensive public support resources, FAQs, and user manuals. While specific documentation for the KardiaAI API library isn't detailed, the company's overall commitment to comprehensive support and documentation for its products suggests a stronger offering compared to the lack of specific information for cmAngio.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | KardiaAI |
|---|---|---|
| Name | cmAngiou00ae | KardiaAI |
| Company | CureMetrix | AliveCor |
| Description | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | FDA-cleared AI software library for analyzing ambulatory ECG rhythms, detecting various cardiac conditions like AFib, bradycardia, and tachycardia. |
| Primary Function | AI-based detection of Breast Arterial Calcifications (BAC) | AI-powered ECG analysis library for detection of various cardiac conditions |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and KardiaAI.
Frequently Asked Questions
More Comparisons
More matchups featuring cmAngio® or KardiaAI
Backers
Who funded each tool's parent company.